(R)-BPO-27是BPO-27的R型对映体，同时也是一种有效的口服活性CFTR抑制剂，其作用方式为ATP竞争性抑制，抑制该蛋白活性的IC₅₀值达4nM。
[1] Kim Y, Anderson MO, Park J, Lee MG, Namkung W, Verkman AS. Benzopyrimido-pyrrolo-oxazine-dione (R)-BPO-27 Inhibits CFTR Chloride Channel Gating by Competition with ATP. Mol Pharmacol. 2015 Oct;88(4):689-96. doi: 10.1124/mol.115.098368. Epub 2015 Jul 14. PMID: 26174774; PMCID: PMC4576686.[2]Cil O, Phuan PW, Gillespie AM, Lee S, Tradtrantip L, Yin J, Tse M, Zachos NC, Lin R, Donowitz M, Verkman AS. Benzopyrimido-pyrrolo-oxazine-dione CFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins. FASEB J. 2017 Feb;31(2):751-760. doi: 10.1096/fj.201600891R. Epub 2016 Nov 8. PMID: 27871064; PMCID: PMC5240666.[3]Snyder DS, Tradtrantip L, Battula S, Yao C, Phuan PW, Fettinger JC, Kurth MJ, Verkman AS. ABSOLUTE CONFIGURATION AND BIOLOGICAL PROPERTIES OF ENANTIOMERS OF CFTR INHIBITOR BPO-27. ACS Med Chem Lett. 2013 May 9;4(5):456-459. doi: 10.1021/ml400069k. PMID: 23814642; PMCID: PMC3694630.
